The FDA issued warnings to telehealth companies and compounding pharmacies about the use of unapproved compounded weight-loss drugs, including versions of semaglutide, tirzepatide, and retatrutide. Hims & Hers Health shares fell 3.2% following the announcement. The FDA highlighted safety concerns such as dosing errors, fraudulent labeling, and improper shipping conditions. It emphasized that these compounded drugs are not FDA-approved and have not been evaluated for safety or effectiveness, signaling increased regulatory scrutiny ahead.

Filing details Dudum’s 22.6M-share stake, including trust holdings, options exercisable within 60 days, and 100% of Hims & Hers’ outstanding Class V stock.

Price-action only: Hims & Hers Health Inc. Class A (HIMS) movements set the tone for institutional models. Understanding the Setup: (HIMS) and Scalable Risk

Hims & Hers Health, Inc. (NYSE:HIMS) has entered Australia, marking its first expansion into the Asia-Pacific market. The move follows its acquisition of Australian digital-health platform Eucalyptus, which includes men’s health brand Pilot and women’s health brand Juniper. Hims is initially rolling out weight-loss and men’s health treatments, with plans to introduce women’s health services […]

Starting today, Hims is officially serving customers in Australia.